CA 27-29
CA 27-29[edit | edit source]
CA 27-29 is a tumor marker that is primarily used in the monitoring of breast cancer. It is a glycoprotein antigen that is associated with the MUC1 protein, which is overexpressed in many breast cancer cells.
Structure and Function[edit | edit source]
CA 27-29 is a circulating antigen that is part of the MUC1 mucin family. Mucins are high molecular weight glycoproteins that play a role in cell signaling and forming protective mucous barriers on epithelial surfaces. In the context of cancer, MUC1 is often overexpressed and aberrantly glycosylated, which can contribute to tumor progression and metastasis.
Clinical Use[edit | edit source]
CA 27-29 is used primarily as a tumor marker in the management of breast cancer. It is not used for screening or diagnosis but is valuable in monitoring disease progression or response to treatment in patients with previously diagnosed breast cancer.
Monitoring[edit | edit source]
The levels of CA 27-29 can be measured in the blood. An increase in CA 27-29 levels may indicate disease progression or recurrence, while a decrease may suggest a positive response to treatment. However, it is important to note that CA 27-29 levels can be elevated in conditions other than breast cancer, such as liver disease, ovarian cancer, and pancreatic cancer.
Limitations[edit | edit source]
While CA 27-29 can be a useful tool in monitoring breast cancer, it has limitations. Not all breast cancer patients will have elevated CA 27-29 levels, and some patients with elevated levels may not have active disease. Therefore, CA 27-29 should be used in conjunction with other diagnostic tools and clinical evaluations.
Comparison with Other Tumor Markers[edit | edit source]
CA 27-29 is often compared with CA 15-3, another tumor marker used in breast cancer management. Both markers are associated with the MUC1 protein, and they have similar clinical applications. However, some studies suggest that CA 27-29 may have slightly better specificity, while CA 15-3 may have better sensitivity.
Conclusion[edit | edit source]
CA 27-29 is a valuable marker in the management of breast cancer, particularly for monitoring treatment response and detecting recurrence. However, its use should be considered as part of a comprehensive approach to patient care, incorporating other diagnostic and monitoring tools.
References[edit | edit source]
- American Cancer Society: Tumor Markers
- National Cancer Institute: Breast Cancer Treatment
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
